RedHill Biopharma Ltd.Find Ratings Reports
REDHILL BIOPHARMA LTD's gross profit margin for the first quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. REDHILL BIOPHARMA LTD has average liquidity. Currently, the Quick Ratio is 1.49 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has increased by 21.52% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY21||Q1 FY20|
|Net Sales ($mil)||20.58||1.06|
|Net Income ($mil)||-22.86||-17.16|
|Balance Sheet||Q1 FY21||Q1 FY20|
|Cash & Equiv. ($mil)||75.99||94.94|
|Total Assets ($mil)||220.12||143.48|
|Total Debt ($mil)||87.55||83.24|
|Profitability||Q1 FY21||Q1 FY20|
|Gross Profit Margin||52.56||72.63|
|Return on Assets||-37.19||-34.56|
|Return on Equity||-154.37||-113.62|
|Debt||Q1 FY21||Q1 FY20|
|Share Data||Q1 FY21||Q1 FY20|
|Shares outstanding (mil)||38.4||35.27|
|Div / share||0.0||0.0|
|Book value / share||1.38||1.24|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||291642.0||593795.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 5.27 indicates a premium versus the S&P 500 average of 4.45 and a significant discount versus the subsector average of 9.60. The price-to-sales ratio is above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, REDHILL BIOPHARMA LTD proves to trade at a discount to investment alternatives.
|RDHL NM||Peers 30.07||RDHL NM||Peers 20.45|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
RDHL's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
RDHL's P/CF is negative making the measure meaningless.
|RDHL NM||Peers 16.33||RDHL NA||Peers 0.52|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
RDHL's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|RDHL 5.27||Peers 9.60||RDHL -31.64||Peers -67.63|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
RDHL is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
RDHL is expected to have an earnings growth rate that significantly exceeds its peers.
|RDHL 3.33||Peers 46.49||RDHL 1395.15||Peers 25.53|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
RDHL is trading at a significant discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
RDHL has a sales growth rate that significantly exceeds its peers.